ReviewCurrent pharmaceutical design2026
Cataract Management in the Modern Era: Therapeutic Advances and Unmet Needs.
Review in Current pharmaceutical design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cataract remains one of the leading causes of blindness worldwide. Studies have shown that its onset is predominantly age-related, particularly affecting the elderly. According to the latest report by the World Health Organization (WHO), more than fifty percent of global blindness cases are attributed to cataracts alone. If timely and appropriate measures are not implemented, this percentage is projected to double in the coming decades. Therefore, there is an urgent need to develop alternative approaches to manage cataracts more effectively, beyond the current reliance on surgical intervention. In recent years, researchers have been actively exploring simpler, non-surgical treatment options that could potentially dissolve cataracts in their early stages. The successful development of such therapies would mark a significant breakthrough and offer immense benefits to humanity. This article highlights the evolution of surgical techniques used in cataract management, from traditional practices to modern innovations, while also discussing emerging non-invasive strategies such as lanosterol-based pharmacotherapy, nanomedicine-driven drug delivery systems, and regenerative approaches like stem cell therapy. These advances signal a promising future for safer, more accessible, and more effective cataract care.
Indexed as
Identifiers
41088906What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.